Biomea Fusion Inc

NASDAQ BMEA

Data sourced from

and

Download Data

Biomea Fusion Inc Shareholders' Equity and Liabilities for the year ending December 31, 2023: USD 199.93 M

Biomea Fusion Inc Shareholders' Equity and Liabilities is USD 199.93 M for the year ending December 31, 2023, a 54.61% change year over year. Shareholders' Equity and Liabilities is the sum of shareholders' equity and total liabilities, representing the company's sources of funding.

Biomea Fusion Inc Shareholders' Equity and Liabilities for the year ending December 31, 2022 was USD 129.31 M, a -30.37% change year over year.
Biomea Fusion Inc Shareholders' Equity and Liabilities for the year ending December 31, 2021 was USD 185.71 M, a 197.00% change year over year.
Biomea Fusion Inc Shareholders' Equity and Liabilities for the year ending December 31, 2020 was USD 62.53 M, a 23,494.72% change year over year.
Biomea Fusion Inc Shareholders' Equity and Liabilities for the year ending December 31, 2019 was USD 265.00 K.

NASDAQ: BMEA

Biomea Fusion Inc

CEO	Mr. Thomas Andrew Butler
IPO Date	April 16, 2021
Location	United States
Headquarters	900 Middlefield Road, Redwood City, CA, United States, 94063
Employees	110
Sector	Healthcare
Industry	Biotechnology

Description

Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.

Key trends